← Research library

Langopept Phase I dose-escalation registration

Planned study · 2019

Registered population or design
42 healthy adults planned at Kazan Federal University. The entry does not report actual enrollment or cohort sizes.
Results availability
MedInvest’s Phase I record lists 42 planned healthy volunteers. Clinomir marks the study completed. Actual enrollment, dose steps and safety results remain unavailable.

Reported findings and study design

The patent gives no measured outcomes

Randomized, double-blind, placebo-controlled, ascending-dose study at Kazan Federal University. The registry identifies G. M. Kamalov as investigator.

Dose, route and schedule

Single and then repeated escalating intramuscular doses versus placebo. The registry lists a 5 mg vial. Dose levels, intervals and duration are unavailable.

Protocol source ↗ · ClinLine trial entry, MedInvest sponsor listing and Kazan Federal University investigator record.

Results · ClinLine trial entry, MedInvest sponsor listing and Kazan Federal University investigator record.
MeasureResultComparison, timing and statistics
Planned enrollment42 healthy volunteers

Source for these results ↗ · Reviewed 2026-11-15

Study limitations and source details

Study limitations

  • The registry lists a study design and formulation strength. It supplies no treatment outcomes or adverse-event counts.

Source details

Trial registry reproduction

ClinLine trial entry, MedInvest sponsor listing and Kazan Federal University investigator record.

Sources checked

Citation

Trial protocol / registrationFull text available

MedInvest. Langopept Phase I dose-escalation registration Russian clinical-trial registry record, authorization 504, 6 September 2019. Protocol LNG-04-2019.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards